dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Cortés Castan, Javier |
dc.contributor.author | Provencher, Louise |
dc.contributor.author | Miller, Kathy |
dc.contributor.author | Chien, A. Jo |
dc.contributor.author | Rugo, Hope |
dc.contributor.author | Wardley, Andrew |
dc.date.accessioned | 2021-06-30T12:25:24Z |
dc.date.available | 2021-06-30T12:25:24Z |
dc.date.issued | 2021-05 |
dc.identifier.citation | Wardley A, Cortes J, Provencher L, Miller K, Chien AJ, Rugo HS, et al. The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer. Breast Cancer Res Treat. 2021 May;187:155-165. |
dc.identifier.issn | 1573-7217 |
dc.identifier.uri | https://hdl.handle.net/11351/6111 |
dc.description | Receptor d’andrògens; HER2; Càncer de mama metastàsic |
dc.description.sponsorship | This work was supported by Astellas Pharma Inc. and Pfizer Inc., the co-developers of enzalutamide (no grant number is applicable). |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Breast Cancer Research and Treatment volume;187 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Medicaments antineoplàstics - Eficàcia |
dc.subject | Mama - Càncer - Quimioteràpia |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | Drug Therapy, Combination |
dc.subject.mesh | Efficacy |
dc.title | The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancer |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s10549-021-06109-7 |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | farmacoterapia combinada |
dc.subject.decs | eficacia |
dc.relation.publishversion | https://link.springer.com/article/10.1007/s10549-021-06109-7 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Wardley A] NIHR Manchester Clinical Research Facility at The Christie NHS Foundation Trust and Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine, and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK. [Cortes J] Division of Breast Cancers and Gynecological Tumors, IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain. Breast Cancer & Melanoma Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Provencher L] Department of Surgery, Centre des Maladies du Sein, CHU de Québec-Université Laval, Québec, Canada. [Miller K] Indiana University Melvin and Bren Simon Cancer Center, Indiana University, Indianapolis, USA. [Chien AJ, Rugo HS] UCSF Comprehensive Cancer Center, University of California, San Francisco, USA |
dc.identifier.pmid | 33591468 |
dc.identifier.wos | 000618588100002 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |